Charles Schwab Investment Management Inc. Acquires 8,913 Shares of Fresenius Medical Care AG (NYSE:FMS)

Charles Schwab Investment Management Inc. lifted its holdings in shares of Fresenius Medical Care AG (NYSE:FMS) by 40.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 31,074 shares of the company’s stock after acquiring an additional 8,913 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Fresenius Medical Care were worth $704,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Smartleaf Asset Management LLC boosted its stake in Fresenius Medical Care by 192.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company’s stock valued at $28,000 after acquiring an additional 806 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Fresenius Medical Care in the third quarter valued at approximately $38,000. Jones Financial Companies Lllp lifted its stake in Fresenius Medical Care by 80.5% in the fourth quarter. Jones Financial Companies Lllp now owns 4,510 shares of the company’s stock valued at $102,000 after purchasing an additional 2,012 shares during the last quarter. Venturi Wealth Management LLC grew its holdings in Fresenius Medical Care by 8.4% during the fourth quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company’s stock valued at $129,000 after purchasing an additional 441 shares during the period. Finally, GAMMA Investing LLC increased its position in Fresenius Medical Care by 43.3% in the fourth quarter. GAMMA Investing LLC now owns 7,164 shares of the company’s stock worth $162,000 after buying an additional 2,166 shares during the last quarter. 8.37% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on FMS shares. Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. Truist Financial lifted their price target on Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research report on Monday, January 6th. Finally, StockNews.com raised Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th.

Fresenius Medical Care Stock Up 0.7 %

Shares of NYSE:FMS opened at $24.94 on Tuesday. The firm has a fifty day moving average price of $24.06 and a two-hundred day moving average price of $22.57. The company has a market cap of $14.64 billion, a price-to-earnings ratio of 20.61, a PEG ratio of 0.76 and a beta of 0.99. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. Fresenius Medical Care AG has a one year low of $17.93 and a one year high of $25.25.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.